Targeting senescence: the new precision arsenal against aging

By Agewell Brief Editorial Desk · Published June 1, 2026 at 8:00 a.m. EDT

Original reporting: Insights into the therapeutic strategies for aging and aging-associated diseases.

A systematic review maps senolytics, senomorphics, and metabolic mimetics—plus AI-driven discovery—to redefine healthspan.

Three things to remember

Senolytics like dasatinib + quercetin clear senescent cells.
Senomorphics such as rapamycin suppress the SASP phenotype.
Caloric restriction mimetics boost autophagy and mitochondrial function.

Source

This signal is based on Insights into the therapeutic strategies for aging and aging-associated diseases. from PubMed. Read the original report for full context.

Health note: Preclinical promise; human efficacy and safety remain unproven.

Pioneer Lineage · Historical Precursors

Scientific Precursors & Foundational Discoveries

1961 Leonard Hayflick

Demonstrated that normal human fibroblasts have a finite replicative lifespan in culture (the 'Hayflick limit'), establishing cellular senescence as a fundamental biological phenomenon. This directly underpins the modern senolytic and senomorphic strategies that target senescent cells to delay aging and treat age-related diseases.

1956 Denham Harman

Proposed the free radical theory of aging, linking mitochondrial reactive oxygen species (ROS) to cumulative cellular damage and age-related decline. This provides the mechanistic basis for metabolic interventions such as caloric restriction mimetics (e.g., spermidine, α-ketoglutarate) that enhance mitochondrial function and reduce oxidative stress, as highlighted in the preprint.

Three things to remember

Source

More on metabolic health